– This year will go down in the history of Polish diabetology as a breakthrough year. Lots of good things happened. We are experiencing a revolution when it comes to the concept of treatment and access to new drugs. From May to September, the Ministry of Health made decisions extending the reimbursement in new groups of drugs. It also introduced the reimbursement of DPP-4 inhibitors, which we did not expect, but at the same time we really needed. Also this year, a decision was made to reimburse, from January 2023, continuous glucose monitoring systems for patients treated with insulin at least three times a day, of any age and with any type of diabetes - said Prof. Leszek Czupryniak, head of the Diabetology and Internal Diseases Clinic of the Medical University of Warsaw, summing up the year that is ending.